The FDA has once again issued a complete response letter to Hengrui and Elevar’s applications for camrelizumab and rivoceranib in first-line liver cancer, with manufacturing again being the issue. More: FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again Source: fierce
read moreJohnson & Johnson will invest $55 billion in the U.S. over the next four years. The announcement comes a month after Eli Lilly revealed a similar U.S.-focused plan to boost its manufacturing base. More: J&J touts B in planned US
read moreA Big Pharma may seem like an incongruous choice of sponsor for a global music competition, but a new initiative from Novartis suggests that its work actually has plenty in common with the 2025 Eurovision Song Contest. More: Novartis links
read moreNovartis’ Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts spotted several shortfalls in the drug’s label, leaving more to be desired—and potential room for improvement for rival Apellis. More: Novartis
read moreDespite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. And now, the Massachusetts-based drugmaker has a fresh FDA approval to support its thesis. More: Alnylam's
read moreHollywood has in recent years been undergoing a much-needed, long-awaited transformation in its portrayals of women and people of color in movies and TV. Now, Eli Lilly is hoping to spark a similar change in how common diseases are represented
read more© 1994 - 2025 B.M. Pharmaceuticals